Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis

American Journal of Hypertension
Søren T KnudsenCarl E Mogensen

Abstract

Elevated pulse pressure (PP) is strongly associated with micro- and macrovascular complications in type 2 diabetic patients. We examined the effect of 12 months of dual blockade with candesartan and lisinopril vs. high-dose lisinopril monotherapy on ambulatory PP in hypertensive type 2 diabetic patients from the CALM (Candesartan and Lisinopril Microalbuminuria Trial) II study. The CALM II study was a 12-month prospective, randomized, parallel-group, double-masked study that included 75 type 1 and type 2 diabetic subjects with hypertension. Participants were randomized for treatment with either high-dose lisinopril (40 mg once daily (o.d.)) or for dual blockade treatment with candesartan (16 mg o.d.) and lisinopril (20 mg o.d.). In this article, we present data from the post-hoc subgroup of 51 type 2 diabetic subjects who completed the full 12-month study period with successful ambulatory blood pressure (BP) measurements at both baseline and follow-up visits. Baseline 24-h BP values were similar in the two groups (24-h systolic BP (SBP) 130 +/- 12 vs. 127 +/- 9, 24-h diastolic BP (DBP) 77 +/- 8 vs. 74 +/- 7, and 24-h PP 53 +/- 8 vs. 53 +/- 7 mm Hg, for the lisinopril and dual blockade groups, respectively, P > 0.2 for all). Com...Continue Reading

References

Mar 23, 1999·American Journal of Nephrology·L A HebertT M O'Dorisio
Oct 29, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·P ClausenB Feldt-Rasmussen
May 31, 2001·Kidney International·R Agarwal
Mar 6, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Rajiv AgarwalKumar Sharma
Mar 7, 2002·Journal of the Renin-angiotensin-aldosterone System : JRAAS·N H Andersen, C E Mogensen
Apr 10, 2002·American Journal of Hypertension·Søren Tang KnudsenCarl Erik Mogensen
May 29, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Peter JacobsenHans-Henrik Parving
Aug 27, 2002·Journal of Hypertension·Miranda T SchramCoen D Stehouwer
Oct 10, 2002·American Journal of Hypertension·Jan A StaessenUNKNOWN Syst-Eur Trial Investigators
Oct 22, 2002·American Journal of Physiology. Endocrinology and Metabolism·S T KnudsenL M Rasmussen
Mar 28, 2003·Journal of the American Society of Nephrology : JASN·Peter JacobsenHans-Henrik Parving
Jun 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Niels H AndersenCarl E Mogensen
Nov 11, 2005·American Journal of Hypertension·John R CockcroftCraig J Currie
Dec 7, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Joon Ho SongMoon-Jae Kim
Jun 15, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·S T KnudsenP L Poulsen

❮ Previous
Next ❯

Citations

Jan 14, 2012·Vascular Health and Risk Management·Relu CernesReuven Zimlichman
Aug 4, 2009·Vascular Health and Risk Management·Khalid AliChristopher J Bulpitt
Sep 20, 2008·American Journal of Hypertension·R David AndersonCarl J Pepine
Feb 13, 2008·American Journal of Hypertension·Michel E Safar
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Jicheng LvGiovanni F M Strippoli
May 31, 2008·Expert Review of Cardiovascular Therapy·Katarzyna Kolasinska-MalkowskaAndrzej Tykarski
Sep 29, 2020·The Journal of Clinical Hypertension·Kevin S TangAnkur D Shah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.